Objective-The goal of this study was to examine the role of endoplasmic reticulum (ER) stress signaling and the contribution of glycogen synthase kinase (GSK)-3␤ activation in hyperglycemic, hyperhomocysteinemic, and high-fat-fed apolipoprotein E-deficient (apoE
A therosclerosis is a disease of the arterial wall that is characterized by inflammation and lipid accumulation. 1 It is the underlying cause of cerebro-and cardiovascular disease that together account for approximately one third of the annual mortality in westernized societies. 1, 2 Risk factors for cardiovascular disease include diabetes mellitus, hypertension, dyslipidemia, hyperhomocysteinemia, abdominal obesity, smoking, and physical inactivity. 3, 4 However, the underlying cellular and molecular pathways that link specific risk factors to accelerated development of atherosclerosis remain unclear. Understanding the mechanisms that promote atherogenesis will be a major step toward the development of novel and effective antiatherosclerotic therapies.
Endoplasmic reticulum (ER) stress is defined as a condition in which the protein processing capacity of the ER is exceeded by nascent proteins, resulting in the accumulation of unfolded or misfolded proteins. The unfolded protein response (UPR) is a cellular self-defense mechanism that alleviates ER stress by limiting de novo protein synthesis, enhancing protein folding capacity, through the upregulation of specific ER chaperones, including glucose-related protein (GRP)78, GRP94, and calreticulin, and increasing the degradation of irreversibly misfolded proteins. 5, 6 If the UPR is insufficient to restore ER homeostasis, proapoptotic signaling factors, such as C/EBP homologous protein, can initiate programmed cell death.
Accumulating evidence supports a causative role for ER stress in the development or progression of atherosclerosis. First, several independent cardiovascular risk factors, including hyperglycemia, 7 hyperhomocysteinemia, 8 obesity, 9 cigarette smoke, 10 and elevated levels of unesterified cholesterol 11 or palmitate, 12, 13 have been associated with activation of the UPR. Second, recent evidence shows that the UPR is specifically activated in atherosclerosis-susceptible regions of the arterial wall, before lesion development. 7, 14 Finally, ER stress-inducing agents can activate/dysregulate metabolic pathways that are directly involved in the development of atherosclerotic lesions. Specifically, we have shown that conditions of ER stress promote lipid accumulation by activating the sterol regulatory element binding proteins, which are transcription factors that control lipid biosynthesis and uptake. 8, 15 ER stress-inducing agents also activate nuclear factor-B, the transcription factor responsible for promoting inflammatory gene expression. 16 In addition, ER stress can activate caspases and promote apoptosis of endothelial cells, macrophages, and other cell types. 17 Together, lipid accumulation, inflammation, and endothelial/macrophage/foam cell apoptosis are hallmark features of atherosclerosis.
The molecular pathways by which ER stress or the UPR activates proatherogenic responses are not known. One potential factor that is involved in ER stress signaling is glycogen synthase kinase (GSK)-3␤, a kinase involved in many metabolic pathways. 18 Conditions of ER stress have been shown to increase the activity of GSK3␤ in cultured cells. Furthermore, GSK3␤ has been shown to play a role in the activation of nuclear factor-B both in vivo and in vitro. 19, 20 Recently, we have found that dietary supplementation with valproate, a small branch chain fatty acid with GSK3 inhibitory properties, 21 can attenuate accelerated atherosclerosis in an streptozotocin-induced hyperglycemic apolipoprotein E-deficient (apoE Ϫ/Ϫ ) mouse model. 22 These were the first reports to implicate GSK3 in the development of atherosclerosis. In this study, we investigated the potential role of ER stress and GSK3 in other models of accelerated atherosclerosis, including hyperhomocysteinemic and highfat-fed mice. In addition, we examined the specific effects of valproate supplementation on vascular and hepatic ER stress and GSK3␤ activity levels in mice. Finally, we examined the mechanisms by which these pro-and antiatherogenic stimuli regulate kinase activity in these different mouse models.
Methods

Mouse Models
Five-week-old female apoE Ϫ/Ϫ (B6.129P2-ApoE tm1Unc ) mice, purchased from the Jackson Laboratory (stock number 002050), were placed on a defined chow diet (TD92078, Harlan Teklad) and randomly divided into 4 groups (nϭ24/group). To induce hyperglycemia, 1 group was injected intraperitoneally with 10 injections of streptozotocin (40 mg/kg per day) as previously described. 23 To induce hyperhomocysteinemia, L-methionine (0.5%, wt/vol) was added to drinking water. To induce relative dyslipidemia, mice were fed a high-fat diet containing 21% milk fat and 0.2% cholesterol (TD97363, Harlan Teklad). The final group remained on the standard chow diet. After 1 week, half of the mice in each group were switched to a diet supplemented with 625 mg/kg sodium valproate (standard plus valproate [TD02165] or high-fat plus valproate [TD06228]). All mice had unrestricted access to both food and water throughout the study. Mice were euthanized at 15 (hyperglycemic, hyperhomocysteinemic) or 24 (high-fat-diet-fed) weeks of age, and blood and tissues were collected for further analysis. The McMaster University Animal Research Ethics Board approved all procedures.
Plasma Analysis
Nonfasting whole blood glucose levels were measured using a DEX glucometer (Bayer). Plasma glucose and lipid levels were determined in nonfasted mice using the colorimetric diagnostic kits for total cholesterol and glucose purchased from Thermal DMA Inc. Plasma valproate concentrations were determined using the AxSYM system (Abbott Laboratories). Plasma homocysteine levels were determined using the IMx system (Abbott Diagnostics). Plasma lipoproteins were separated by fast protein liquid chromatography, and total cholesterol was measured in each fraction.
Immunohistochemical Analysis
Mice were euthanized, and vasculature was flushed with 1 ϫ PBS and perfusion-fixed with 10% neutral buffered formalin. Liver and heart, including the aortic root, were removed and embedded in paraffin. Serial sections (4 m) of aortic root were collected on precoated glass slides for measurement of lesion size (hematoxylin/ eosin staining) or immunohistochemical staining. 24 The Vectastain ABC System was used for immunohistochemical analysis. Sections were stained with primary antibodies and appropriate biotinylated secondary antibodies and visualized using Nova Red. Sections were counterstained with hematoxylin. Serial sections were stained with preimmune IgG, in place of primary antibodies, to control for nonspecific staining. Images were captured with an Olympus microscope and a 12.5-megapixel DP71 digital camera. Phospho-Tyr216-GSK3␤ antibody and total GSK3␤ antibody were purchased from BD Transductions (catalog Nos. 612312 and 610202, respectively), and phospho-Ser9-GSK3␤ antibody was purchased from Cell Signaling Technology (catalog No. 93235). Anti-KDEL antibody was purchased from Assay Designs (catalog No. SPA-827), and anti-C/ EBP homologous protein antibody was purchased from Santa Cruz Biotechnology (catalog No. sc-575).
Immunoblot Analysis
Total protein lysates were solubilized in GSK3 buffer containing 50 mmol/L Tris HCl, pH 8.0, 150 mmol/L NaCl, 5 mmol/L EDTA, 50 mmol/L NaF, 1% Triton X, 10 mmol/L dithiothreitol, 1 mmol/L benzamidine, 1 mmol/L phenylmethylsulfonyl fluoride, and PhosS-TOP Phosphatase Inhibitor (Roche). Protein lysates were diluted in SDS-PAGE gel loading buffer, resolved by SDS-PAGE, and transferred to nitrocellulose membranes. After incubation with the appropriate primary and horseradish peroxidase-conjugated secondary antibodies (Life Technologies), membranes were developed using the Immobilon Western chemiluminescent horseradish peroxidase substrate (Millipore).
Anti-KDEL (GRP78/94) antibody and protein disulphideisomerase antibody were purchased from Assay Designs (catalog Nos. SPA-827 and SPA-891, respectively), and ␤-actin antibody was purchased from Sigma-Aldrich (catalog No. A3854). PhosphoTyr216-GSK3␤ antibody and total GSK3␤ antibody were purchased from BD Transductions (catalog Nos. 612312 and 610202, respectively), and phospho-Ser9-GSK3␤ antibody was purchased from Cell Signaling Technology (catalog No. 93235).
GSK3␤ Activity Assay
GSK3␤ was immunoprecipitated from 900 g of total mouse liver protein in GSK3 buffer using a monoclonal antibody specific for GSK3␤ (catalog No. 610202, BD Transductions) and Ultra Link immobilized Protein A Plus (Pierce). Kinase activity was measured by monitoring the incorporation of 32 After 60 minutes at room temperature, samples were placed on ice and then spotted onto Whatman P81 phosphocellulose paper and washed 3 times with 0.75% o-phosphoric acid and once with acetone. 32 P incorporation onto the substrate was determined by scintillation counting, and total counts minus background are reported.
Lipid Staining
Liver cryosections, 7 m thick, were collected on slides and fixed in formal calcium for 30 minutes. Neutral lipids were visualized using Oil Red O as described previously. 8 Relative amounts of lipid staining were quantified using ImageJ 1.35 software.
For en face staining, descending aortas were collected and periadventitial tissue was removed. Clean aortas were washed in 70% ethanol, stained with 0.5% Sudan IV for 15 minutes, destained with 80% ethanol, and rinsed with dH 2 O. After longitudinal dissection, stained aortas were mounted en face, and the images were visualized and captured using a Leica surgical microscope and a DC300 digital camera with IM50 software.
Cell Culture
HepG2 cells were cultured in Dulbecco's modified Eagle's medium (Invitrogen) with 10% fetal bovine serum at 37°C and 5% CO 2 . Cells were treated with 8 g/mL tunicamycin or 250 mol/L bovine serum albumin-coupled palmitic acid for 8 hours. Oil Red O stain was applied to cells, and after washing with PBS and 60% ethanol, the cells were fixed in 2.5% paraformaldehyde. Images were captured with an Olympus microscope and a 12.5-megapixel DP71 digital camera. Intensity of staining was quantified using ImageJ software.
Statistical Analysis
Results are presented as the meanϮstandard deviation. The Student t test was used to assess differences between experimental groups and controls. Probability values of Ͻ0.05 were considered statistically significant.
Results
Mouse Models of Accelerated Atherosclerosis
We directly compared the effects of chronic hyperglycemia, hyperhomocysteinemia, or high-fat diet on ER stress levels, GSK3␤, and accelerated atherosclerosis in apoE Ϫ/Ϫ mice (Table) . Hyperglycemia was induced with multiple low-dose injections of streptozotocin (40 mg/kg body weight) in 5-week-old apoE Ϫ/Ϫ mice. At 15 weeks of age, nonfasting blood glucose levels had increased to 23.2Ϯ5.6 mmol/L compared with 10.5Ϯ2.0 mmol/L in controls (PϽ0.05). Hyperhomocysteinemia was induced by adding 0.5% methionine (wt/vol) to the drinking water starting at 5 weeks of age. In the methionine-supplemented group, plasma homocysteine levels increased to 14.1Ϯ4.0 mol/L compared with 4.6Ϯ0.8 mol/L in controls (PϽ0.05). ApoE Ϫ/Ϫ mice fed a high-fat diet containing 21% milk fat and 0.2% cholesterol had a significant increase in total plasma cholesterol (25.0Ϯ3.6 mmol/L versus 14.8Ϯ2.7 mmol/L in controls, PϽ0.05) and blood glucose (11.2Ϯ0.9 mmol/L versus 8.5Ϯ0.3 mmol/L in controls, PϽ0.05). Subsets of mice from each group were fed diets supplemented with 625 mg/kg sodium valproate. Valproate has been shown to inhibit GSK3␤ activity both in vitro and in vivo. 21, 22, 25, 26 Plasma valproate concentration in supplemented mice was 33 to 54 mol/L with the exception of the high-fat-diet mice in which it was significantly lower (7 mol/L). The reason for this is not clear; however, it is possible that conditions of severe dyslipidemia may affect valproate uptake, clearance, or detection. Plasma homocysteine levels were lower in hyperglycemic mice compared with the normoglycemic treatment groups. This effect may result from insulin deficiency and has been previously noted in both animal models and young patients with diabetes mellitus. 27, 28 Valproate supplementation did not significantly affect blood glucose or plasma homocysteine concentrations in any of the groups (Table) . In hyperglycemic and hyperhomocysteinemic mice, total plasma cholesterol and plasma lipid profiles were similar to those of control mice (Table and Supplemental Figure I , available online at http://atvb.ahajournals.org). As expected, a high-fat diet was associated with increased total plasma cholesterol relative to standard chow fed controls. Valproate supplementation did not affect plasma lipid profiles in hyperglycemic or hyperhomocysteinemic mice and was associated with a slight, nonsignificant decrease in very-low-density lipoprotein-and low-density lipoprotein-sized particles in high-fat-fed mice.
The Effects of Valproate Supplementation on Accelerated Atherosclerosis
Both hyperglycemia and hyperhomocysteinemia significantly increased mean atherosclerotic lesion volume at the aortic root of 15-week-old female apoE Ϫ/Ϫ mice ( Figure 1 and Table) . Mice fed valproate-supplemented diets had significantly reduced cross-sectional lesion area and total mean lesion volume than the mice fed control diet (4.98Ϯ0.76 versus 8.62Ϯ1.23ϫ10
Ϫ3 mm 3 , PϽ0.05, in hyperglycemic (Figure 1 and Table) . Atherosclerotic lesions from each group were further characterized by measuring necrotic area. Plaque necrosis, defined as acellular regions of the lesion, was quantified and is presented relative to total lesion volume. Hyperglycemic, hyperhomocysteinemic, and high-fat-fed mice had significantly increased levels of necrosis within lesion areas relative to controls ( Figure 1C) . With valproate supplementation, the proportion of necrosis was significantly reduced in all models ( Figure 1C) .
Atherosclerotic lesion areas were determined in descending aortas by staining en face with Sudan IV. Few lesions were found in the descending aortas of 15-week-old control, hyperglycemic, or hyperhomocysteinemic apoE Ϫ/Ϫ mice (data not shown). At 24 weeks of age, however, there was detectable lesion development along the entire aorta. High-fat feeding increased atherosclerotic lesion areas approximately 3-fold relative to age-matched controls (Supplemental Figure  II) . Similar to the effects observed at the aortic sinus, valproate supplementation significantly reduced lesion area in the descending aorta (Supplemental Figure II) .
Hepatic and Aortic ER Stress Levels
Immunohistochemical and immunoblot analyses were used to evaluate ER stress levels in the different experimental groups. Consistent with previous observations, 8, 23 hyperglycemia, hyperhomocysteinemia, and high-fat feeding were each associated with increased ER stress response protein expression. Immunoblot analysis of hepatic GRP78, GRP94, and protein disulphide-isomerase protein levels showed significantly elevated levels of all ER stress markers in each of the mouse models (Figure 2A and 2B) . Aortic immunohistochemical analysis demonstrated increased expression of GRP78/94 and C/EBP homologous protein by probing with anti-KDEL and anti-C/EBP homologous protein antibodies, respectively ( Figure 2C and 2D) . Valproate supplementation did not significantly alter the intensity or staining pattern of the ER stress response proteins, nor did it significantly affect the levels of ER stress markers in any of the models and tissues examined.
Lipid Accumulation and the Effects of Valproate Supplementation
Diabetes mellitus, severe hyperhomocysteinemia, and highfat diet have each been associated with the accumulation of hepatic lipids, leading to nonalcoholic fatty liver. 8, 29 Conditions of ER stress have been shown to promote lipid accumulation in specific cell types, including hepatocytes, by dysregulating sterol regulatory element binding protein-controlled cholesterol and triglyceride biosynthesis and uptake. 30 We quantified the relative hepatic neutral lipid levels in our hyperglycemic, hyperhomocysteinemic, and high-fat-fed apoE Ϫ/Ϫ mice by Oil Red O staining of frozen liver sections ( Figure 3A) . Results show a significant accumulation of hepatic lipid in each of the models, relative to controls. In hyperglycemic and hyperhomocysteinemic mice, valproate supplementation significantly reduced lipid concentrations to levels observed in the age matched control mice. High-fatfed mice showed no significant change in hepatic lipid levels when supplemented with valproate ( Figure 3B ).
The Role of GSK3␤ in ER Stress-Induced Lipid Accumulation
To begin to examine the specific role of GSK3␤ in lipid accumulation, HepG2 cells were cultured in the presence of ER stress-inducing agents tunicamycin (8 g/mL) or palmitic acid (250 mol/L). Consistent with previous findings, conditions of ER stress were associated with significant intracellular lipid accumulation as determined by Oil Red O staining (Supplemental Figure III) . Pretreatment of cells with 5 mmol/L valproate or 200 mol/L of a specific GSK3 inhibitor, GSK3 inhibitor II, attenuated lipid accumulation. This finding indicates that GSK3␤ activity is required for ER stress-induced lipid accumulation and is consistent with our hypothesis that ER stress signals through GSK3␤ and that valproate blocks ER stress-induced GSK3␤ activity.
GSK3␤ Regulation in Mouse Models of Accelerated Atherosclerosis
To determine the relative effects of hyperglycemia, hyperhomocysteinemia, and high-fat diet on hepatic GSK3␤ activity, we immunoprecipitated total GSK3␤ from homogenized liver lysates and monitored its ability to incorporate 32 P into a phospho-primed glycogen synthase peptide (p-GS2) substrate. We found that conditions and treatments that increased ER stress levels and accelerated atherosclerosis were associated with significantly enhanced GSK3␤ activity ( Figure 4A ). Dietary supplementation with valproate attenuated activation of GSK3␤ in hyperglycemic, hyperhomocysteinemic, and high-fat-fed mice but had no effect on basal level GSK3␤ activity in control mice.
GSK3␤ can be regulated by posttranslational phosphorylation of specific tyrosine and serine residues that can enhance (phospho-Tyr216) or inhibit (phospho-Ser9) GSK3␤ kinase activity. 31, 32 We investigated the phosphorylation status of GSK3␤ by immunoblot analysis of protein isolated from mouse liver using antibodies specific for total GSK3␤, phospho-Ser9-GSK3␤, or phospho-Tyr216 GSK3␤. Phosphorylated GSK3␤ levels were normalized to total GSK3␤ for each treatment group. Our results show that conditions of hyperglycemia, hyperhomocysteinemia, and high-fat feeding do not significantly affect total GSK3␤ or phospho-Ser9-GSK3␤ levels ( Figure 4B and 4C ). Dietary supplementation with valproate did significantly increase the relative levels of phosphorylation on Ser9 in each of the treatment groups. This finding is consistent with the observed attenuation of GSK3␤ activity in liver lysates from valproate-supplemented mice ( Figure 4A) . Hyperglycemia, hyperhomocysteinemia, and high-fat feeding were associated with increased levels of phospho-Tyr216-GSK3␤ relative to the control groups. Dietary supplementation with valproate appeared to reduce Tyr216 phosphorylation to basal levels in the treatment groups and had no effect on Tyr216 phosphorylation in the control group. Together, these results suggest that GSK3␤ activity is regulated, at least in part, by ER stress and valproate-induced changes in phosphorylation patterns.
Immunohistochemical staining was performed on fixed cross-sections of aortic root to determine whether the correlation between ER stress and the activation of GSK3␤ observed in the liver was also present in the developing atherosclerotic lesion. Sections stained with an antibody specific for phospho-Ser9-GSK3␤ showed increased staining in the vessel wall of mice fed a valproate-supplemented diet relative to mice fed a nonsupplemented standard diet ( Figure  5A ). The presence of hyperglycemia, hyperhomocysteinemia, or relative dyslipidemia was associated with increased levels of phospho-Tyr216-GSK3␤ ( Figure 5B ). Mice receiving valproate supplementation had decreased phospho-Tyr216 staining relative to nonsupplemented controls. Generally, staining was most intense in the macrophage foam cells within the atherosclerotic lesion. Total GSK3␤ protein levels were not significantly affected by any of the treatments (data not shown). These results suggest that GSK3␤, in the liver and the atherosclerotic lesion, is regulated in a similar manner in response to proatherosclerotic stimuli and valproate supplementation.
Discussion
A diverse but finite array of risk factors has been associated with the development of cardiovascular disease. These include dyslipidemia, smoking, stress, diabetes mellitus, hypertension, obesity, and a sedentary lifestyle. 3 Despite considerable advances, our understanding of the molecular mechanisms by which multiple risk factors actively promote atherosclerosis, the underlying cause of myocardial infarction, remains incomplete.
In this study, we investigated the potential role of ER stress signaling and GSK3␤ activation in the development and progression of atherosclerosis induced by 3 established cardiovascular risk factors. We found elevated levels of diagnostic markers of ER stress and increased GSK3␤ activity in the livers and atherosclerotic lesions of hyperglycemic, hyperhomocysteinemic, and high-fat-fed mice relative to age matched controls. There was a direct correlation between these changes and the accelerated development of atherosclerosis in each of the mouse models. Mice fed a diet supplemented with valproate exhibited ER stress levels similar to those of nonsupplemented controls but had attenuated GSK3␤ activity and significantly reduced atherosclerotic lesion volume. Together, these data support a role for ER stress-induced GSK3␤ activity in the accelerated development of hepatic steatosis and atherosclerosis in apoE Ϫ/Ϫ mice and identify GSK3␤ as a potential target for antiatherogenic interventions.
Elevated levels of ER stress have previously been observed in mouse models of hyperglycemia, 7 hyperhomocysteinemia, 8 and obesity. 9 The molecular mechanisms by which these conditions promote ER stress and activate the UPR are not fully understood. In cultured cells, both low and high concentrations of glucose have been associated with ER stress, and the glucose metabolite glucosamine is an especially potent ER stress-inducing agent. 23, 33 Alterations in intracellular glucose concentration may disrupt ER homeostasis by interfering with the N-linked glycosylation of proteins, a major factor in proper protein folding; however, there is little direct evidence for this at the present time. Elevated concentrations of homocysteine are associated with ER stress and induction of the UPR in cultured cells, as well as in animal models of hyperhomocysteinemia. 8, 34 It has been suggested that the free thiol of homocysteine can interfere with disulfide bond formation-an essential event in the proper folding of many proteins in the ER. 35 There is also evidence that elevated homocysteine concentration disrupts Ca 2ϩ homeostasis in the ER. 36 The mechanism by which high-fat feeding or the resulting dyslipidemia may promote ER stress is not completely understood. Specific lipids, including palmitate and unesterified cholesterol, have been shown to induce the UPR in cultured cells, perhaps by directly altering the consistency and function of the ER membrane. 11, 13 More recently, other factors and conditions associated with cardiovascular risk have been shown to promote ER stress, including cigarette smoke and obesity. 9, 10 The association of multiple risk factors with ER stress suggests that activation of ER stress response pathways play a central role in accelerated atherosclerosis. Therefore, it is important to investigate how ER stress activates proatherogenic mechanisms.
The UPR intersects directly and indirectly with many different stress-signaling pathways. There is increasing evidence of the ability of ER stress to signal through GSK3. 18, 37, 38 GSK3␣ and ␤ are homologous, ubiquitously expressed serine/threonine kinases that are involved in a variety of intracellular signaling pathways. 39 Dysregulation of GSK3 activity has been implicated in the development of cancer, Alzheimer disease, bipolar disorder, cardiac myopathy, and insulin resistance. 40 We have shown that GSK3-deficient cultured mouse embryonic fibroblasts are protected from glucosamine-induced lipid accumulation and that this effect could be mimicked by pretreatment of wild-type mouse embryonic fibroblasts with valproate or other compounds with GSK3 inhibitory properties. 22 Recently, it has been shown that GSK3 inhibition attenuates ER stress-induced lipid-associated apoptosis in cultured hepatocytes. 41 These findings directly lead to the experiments described in this report that tested the ability of valproate to attenuate accelerated atherosclerosis in apoE Ϫ/Ϫ mouse models. Intracellular control of GSK3␤ activity is relatively complex and can be modulated through interactions with a number of different scaffold proteins (axin, adenomatous polyposis coli), as well as intracellular localization. 42 Regulation appears to predominantly occur by phosphorylation and dephosphorylation of specific residues. GSK3␤ activity is inhibited by phosphorylation of an amino-terminal serine residue (Ser9). 31 Most evidence suggests that Akt is responsible for phosphorylating Ser9 of GSK3␤; however, other kinases may also play a role. 43 Activation of GSK3␤ has been associated with phosphorylation of a specific tyrosine residue (Tyr216). 32, 44 Lochhead et al have suggested that nascent GSK3␤ acts as a tyrosine kinase that autophosphorylates Tyr216 during a protein maturation process. 45 Other studies have shown that Tyr216 phosphorylation/dephosphorylation is used as a mechanism to activate/inhibit the mature GSK3␤ Figure 4 . Hepatic glycogen synthase kinase (GSK)-3␤ activity and phosphorylation in hyperglycemic, hyperhomocysteinemic, and highfat-diet-fed mice. A, GSK3␤ was immunoprecipitated from total protein lysates prepared from the livers of control (C), hyperglycemic (HG), high-fat-diet-fed (HF), and hyperhomocysteinemic (HH) mice with or without valproate supplementation, as indicated. GSK3␤ kinase activity was determined by monitoring 32 P incorporation onto a phospho-primed glycogen synthase derived peptide (pGS2). Activities are presented relative to unsupplemented control. B, Immunoblot analysis of total protein isolated from C, HG, HF, or HH liver in the presence or absence of valproate supplementation, as indicated. Total protein lysates were resolved by SDS-PAGE, transferred to nitrocellulose membranes, and immunostained with antibodies specific for phospho-Ser9 (S 9 )-GSK3␤, phospho-Tyr216 (Y 216 )-GSK3␤, total GSK3␤, or ␤ actin, as indicated. C, All protein levels were quantified by densitometry, and phospho-S 9 -GSK3␤ and phospho-Y 216 -GSK3␤ were normalized to total GSK3␤ and presented relative to the levels found in nonsupplemented control liver. *PϽ0.05 relative to nonsupplemented control, #PϽ0.05 relative to nonsupplemented mice from the same treatment group. nϭ6 to 8 per group.
protein. 46 The hierarchal relationships of these multiple GSK3 regulatory pathways are still being deciphered.
Our findings suggest that atherogenic risk factors induce ER stress, which leads to the activation of GSK3␤, in hepatocytes and macrophage foam cells within the atherosclerotic lesion. Our results suggest that conditions of ER stress activate GSK3␤ by increasing the relative phosphorylation of Tyr216. Furthermore, we show that valproate, in addition to its ability to directly inhibit GSK3␤, 21 can also alter the phosphorylation status of GSK3␤. Specifically, in vivo treatment with valproate is associated with a relative increase in the phosphorylation of Ser9 and decreased phosphorylation of Tyr216. The mechanisms by which this occurs have yet to be determined but likely involve the ability of valproate to interact with upstream kinases or phosphatases. Previous studies have suggested that valproate can affect GSK3␤ activity by inhibition of Akt. 26 Valproate is a potent and commonly prescribed drug that acts both as an anticonvulsant in the treatment of epilepsy and as a mood stabilizer to control bipolar disorder. 47 A recently published pharmacoepidemiological study has shown that epileptic patients taking valproate have a significantly reduced risk of myocardial infarction. 48 Despite its wide use, the specific molecular mechanism(s) responsible for the clinical efficacy is not known. Exposure to millimolar concentrations of valproate can induce a variety of cellular responses that may be responsible for its clinical effectiveness. In addition to its ability to inhibit GSK3, it has been reported that valproate potentiates GABA-mediated postsynaptic inhibition, 49 depletes intracellular inositol concentrations, 50 inhibits histone deacetylases, 51 and induces the expression of cellular chaperones. 52, 53 Our data are consistent with a mechanism by which the antiatherogenic effects of valproate are conferred by its ability to inhibit GSK3␤ activity. In support of this hypothesis, we show that valproate and another, more specific inhibitor of GSK3 attenuate ER stress-induced lipid accumulation in cultured cells. In addition, we have previously shown that valproate protects cultured cells from ER stress-induced apoptosis. 53 Together, these findings may explain the reduction in total volume and the decreased necrotic area of atherosclerotic lesions in valproate-supplemented mice. Additional studies, perhaps using GSK3-deficient mice, will be required to further test the role of GSK3 in proatherogenic signaling pathways.
These studies identify a role for ER stress-GSK3 signaling in the progression and development of atherosclerosis. Furthermore, they suggest a mechanism by which pro-and antiatherogenic signals are transmitted via alterations to the phosphorylation status of GSK3␤. This is potentially an important step toward our overall understanding of the molecular and cellular mechanisms that lead to cardiovascular disease in that it may provide a new and unexplored class of targets for the development of antiatherogenic drug therapeutics. 
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